Mira Pharmaceuticals (MIRA) Total Non-Current Liabilities (2022 - 2023)
Mira Pharmaceuticals' (MIRA) quarterly Total Non-Current Liabilities came in at $558097.0 in Q4 2023, down 58.79% year-on-year from $1.4 million in Q4 2022, and down 58.79% quarter-over-quarter from $1.4 million in Q4 2022.
Mira Pharmaceuticals (MIRA) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Mira Pharmaceuticals has disclosed Total Non-Current Liabilities across 2 years of filings, most recently posting $558097.0 for Q4 2023.
- Total Non-Current Liabilities for Q4 2023 came in at $558097.0, down 58.79% year-over-year; the trailing twelve-month figure through Dec 2023 was $558097.0 (down 58.79% YoY), and the FY2023 annual result was $558097.0, down 58.79% from the prior year.
- Total Non-Current Liabilities came in at $558097.0 for Q4 2023 at Mira Pharmaceuticals, down from $1.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.4 million in Q4 2022 to a low of $558097.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -31.03 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Mira Pharmaceuticals | 22.73 Mn | 11.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 558,097.00 |
| Dec 31, 2022 | 1.35 Mn |